Where DNA Breaks
Our Insight Begins
Where DNA Breaks
Our Insight Begins
GET TO KNOW OUR PLATFORM
STRIDE® Spotlight
Direct
Directly detects free DNA ends in situ
Quantitative
Automated and objective quantification of fluorescent foci by in-house built AI algorithms
Compatible
Applicable with various types of biological material, including patient-derived tissue samples
Sensitive
Reliable measurement of DNA damage at individual lesion level
Specific
Selective detection of single-, double-, or repair protein-associated DNA breaks
intoDNA as a Partner
Expertise
The STRIDE® platform delivers advanced DNA damage analysis, ensuring you gain critical insights for informed decision-making at every stage.
Services
Elevate your research outcomes with our end-to-end service tailored to your needs. We seamlessly integrate with your chosen biological model and multiplex our assays to help your research reach its fullest potential.
Mission
We know existing modalities can fall short. We envision a future where the right therapies reach the right patients, at the right time.
Global Expertise
We support top pharmaceutical companies, small-to-mid-sized biotechs and research laboratories across the globe.
0.5K+
scientists
100+
candidates
10K+
9/10
top big pharma
0.5K+
scientists
100+
candidates
10K+
9/10
top big pharma
Latest News
intoDNA Presents Data on Two Novel Assays, sSTRIDE-NER and sSTRIDE-PARP1, in Poster Presentations at the 2026 AACR Annual Meeting
intoDNA Presents Data on Two Novel Assays, sSTRIDE-NER and sSTRIDE-PARP1, in Poster Presentations at the 2026 AACR Annual Meeting
intoDNA to Present Two Poster Presentations at the 2026 AACR Annual Meeting
intoDNA Forms Strategic Advisory Board with Leading Diagnostics and Precision Oncology Experts
